HOUSTON, Oct. 26, 2016 /PRNewswire/ -- A class-action lawsuit filed against pharmaceutical giant Mylan Inc. (NASDAQ:
The lawsuit filed by The Lanier Law Firm and Sharp Law on behalf of consumers who have purchased EpiPen injectors charges that Mylan began a series of aggressive price increases shortly after it acquired the rights to sell the EpiPen in 2007. Mylan required consumers to purchase the EpiPen in pairs and raised the retail price from $57 in 2007 to more than $600 today, even though pharmaceutical industry sources estimate each injector can be produced for less than $30.
"Mylan CEO Heather Bresch knows that good hardworking Americans will do anything to protect loved ones from a deadly allergic reaction that could happen at any time," said attorney Mark Lanier, founder of The Lanier Law Firm. "This company's attempt to saddle consumers, insurance companies, Medicare and Medicaid with the bill for its outrageously overpriced product is indefensible."
For more information about the lawsuits, visit www.lanierlawfirm.com.
Mylan closely protects its monopoly on the EpiPen, which delivers life saving medicine to fend off allergic reactions. The company's pricing scheme results in excessive out-of-pocket expenses for the uninsured and those with high-deductible health insurance. Mylan is currently under investigation by the House Committee on Oversight and Government Reform, the Securities and Exchange Commission and state regulatory authorities for its EpiPen pricing scheme.
The lawsuit, Rosetta Serrano and Shannon Clements et al. vs. Mylan N.V., Mylan Specialty L.P., is filed in the U.S. District Court for the District of Kansas (Case No. 16-2711) on behalf of potentially thousands of consumers who have purchased an EpiPen.
With offices in Houston, New York and Los Angeles, The Lanier Law Firm is committed to addressing client concerns with effective and innovative solutions in courtrooms across the country. The firm is composed of outstanding trial attorneys with decades of experience handling cases involving pharmaceutical liability, asbestos exposure, commercial litigation, product liability, personal injuries, maritime law, and sports and entertainment law.
For more information, contact J.D. Cargill at 1.800.723.3216 or firstname.lastname@example.org.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/epipen-maker-mylan-hit-with-class-action-lawsuit-300351794.html
SOURCE Lanier Law Firm
Subscribe to our Free Newsletters!
Nocturnal polyuria refers to increased urine output during night, without an associated increase in ...
Nootropics are drugs or substances which improve cognition that are being increasingly used ...
Pterygium or Surfer's eye is described as a proliferative disorder of the ocular surface possibly ...View All